Adial Pharmaceuticals, Inc. Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature
Adial Pharmaceuticals, Inc. (ADIL) reported Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature of $52.05 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2020-03-20.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature · last filed 2020-03-20
- Adial Pharmaceuticals, Inc. adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2018-12-31 was $0.00.
- Adial Pharmaceuticals, Inc. adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2018-09-30 was $0.00.
- Adial Pharmaceuticals, Inc. adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2018-06-30 was $52.05K.
- Adial Pharmaceuticals, Inc. adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2018 was $52.05K.
| Period end | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 3 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 6 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 9 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 12 month |
|---|---|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-20 | $0.00 derived: sum of 2 quarters · filed 2020-03-20 | $52.05K derived: sum of 3 quarters · filed 2020-03-20 | $52.05K 10-K · filed 2020-03-20 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $52.05K derived: sum of 2 quarters · filed 2019-11-14 | $52.05K 10-Q · filed 2018-11-14 | |
| 2018-06-30 | $52.05K 10-Q · filed 2019-11-14 | $52.05K 10-Q · filed 2018-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |